26 April 2016 Detection of capecitabine (Xeloda®) on the skin surface after oral administration
Author Affiliations +
J. of Biomedical Optics, 21(4), 047002 (2016). doi:10.1117/1.JBO.21.4.047002
Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p<0.001. The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.
© 2016 Society of Photo-Optical Instrumentation Engineers (SPIE)
Mao-Dong Huang, Harald Fuss, Jürgen M. Lademann, Stefan Florek, Alexa Patzelt, Martina C. Meinke, Sora Jung, "Detection of capecitabine (Xeloda®) on the skin surface after oral administration," Journal of Biomedical Optics 21(4), 047002 (26 April 2016). https://doi.org/10.1117/1.JBO.21.4.047002

Back to Top